Video Reports

Embed this video

Copy Code

Link to this video

Get LinkEmbedLicenseRecommend (-)Print
Bookmark and Share

By Christine Benz | 04-11-2010 06:00 AM

Healthy Growth Prospects for This Pharma Pick

Day 7: Growth from emerging markets as well as launched and pipeline products bode well for this pick.

Christine Benz: Hi. I'm Christine Benz from Morningstar. You have until April 15 to fund an IRA for the 2009 tax year, so all this week I will be talking to some of Morningstar's top experts to get their best ideas for funding an IRA.

I'm here today with Damien Conover. Damien is an equity strategist, and he is also editor of the Morningstar Healthcare Observer. Damien, thanks so much for being here.

Damien Conover: Thanks for having me.

Benz: So, we've recently seen, over just even the past couple weeks, very few 4- and 5-star stocks at this point. Yet, your pick today is a 5-star company currently. Tell us what it is and why you like it.

Conover: The company is Novartis, ticker symbol NVS, and the reason why we like it is a couple things. One, the valuation of the company is very attractive. Two, it's growth prospects are very attractive as well. And when I say growth prospects, the main thing I'm talking about are its currently launched products as well as its pipeline products, both of which are very well poised for growth over the next two to three years.

Read Full Transcript
{0}-{1} of {2} Comments
{0}-{1} of {2} Comment
  • This post has been reported.
  • Comment removed for violation of Terms of Use ({0})
    Please create a username to comment on this article